Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A synthesis method and technology of cediranib, applied in the field of medicinal chemistry synthesis, can solve the problems of carbonization of products, difficult purification of products, large solid residues and the like
Inactive Publication Date: 2012-07-25
CHEMPROSPECT PHARMTECH
View PDF7 Cites 11 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The zinc powder reduction used in this method is difficult to post-process and produces a large amount of solid residue. Using formamide as a cyclization reagent requires high temperature (190°C) and long-term reaction, which is easy to carbonize the product and generate impurities.
WO2006117552A1 uses iron powder for reduction, and also uses formamide as a cyclization reagent, which will lead to difficult post-processing and difficult purification of the product
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0086] 1) Chemical synthesis of ethyl 2-(2,3-difluoro-6-nitrophenyl)-3-acetoacetate (X1)
[0087] Dissolve 68g (1mol) of sodium ethoxide in 300ml of anhydrous tetrahydrofuran, stir mechanically and cool down to 10°C, add 130g (1mol) of ethyl acetoacetate, dropwise complete within about 1 hour, and control the temperature below 35°C. Dissolve 88.5 g (0.5 mol) of 1,2,3-trifluoro-4-nitrobenzene in 200 ml THF, and add dropwise into the above reaction solution under ice-cooling conditions. The reaction was naturally raised to room temperature and stirred for 5 h, and the completion of the reaction was monitored by TLC.
[0088] Pour 500ml of 1N hydrochloric acid aqueous solution to quench, extract with ethyl acetate (1L*3), combine the organic phases, wash the organic phase with saturated brine, spin dry to obtain 241g of product, yield: 84%.
[0089] The structure of the product was confirmed by NMR:
[0090] 1 H NMR Spectrum (CDCl 3 ): δppm 13.21(s,1H),7.87(m,1H),7.30(t,1H),4.2...
Embodiment 2
[0146] As described in Example 1, the difference is that sodium hydride is used in step (1), the molar ratio of the reaction materials is the same, and 125 g of the product is obtained by the reaction, and the yield is 44%.
Embodiment 3
[0148] As described in Example 1, the difference is that potassium tert-butoxide is used in step (1), the molar ratio of the reaction materials is the same, and 153 g of the product is obtained after the reaction, and the yield is 54%.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses a preparation method of cediranib, which comprises the following steps of using trifluoro-nitrobenzene as a raw material and performing acetyl methyl adding, substitution, cyclization and protection to obtain a segment 1; and then using methyl vanillate as the raw material, performing benzyl bromine protection, nitro adding, reduction, unique cyclization and chlorination to obtain a segment 2; and performing nucleophilic substitution and deprotection on the two segments to obtain the final product cediranib. Compared with other methods, the preparation method of the cediranib has the advantages of mild reaction condition, high yield and scale amplification, and raw materials can be obtained easily.
Description
technical field [0001] The invention relates to the preparation of cediranib (Cediranib), which belongs to the field of pharmaceutical chemical synthesis. Background technique [0002] Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of pan-vascular endothelial growth factor (pan-VEGF) receptor tyrosine kinase. This is an oral chemotherapy drug that AstraZeneca is developing as a possible treatment for cancer. [0003] In antitumor treatment, chemotherapy is a widely used systemic treatment, which can be used alone or in combination with other methods, even for middle and advanced cancers that cannot be treated by surgery. In recent years, with the rapid development of chemotherapy pharmacology and cell molecular biology, chemotherapy drugs are transitioning from traditional cytotoxic drugs to new anticancer drugs with multiple links and new targets, and cancer cell differentiation inducers, telomerase inhibitors, etc. agent, tumor ge...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more